El interés en corto de EyePoint Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de EyePoint Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

EyePoint Pharmaceuticals (NASDAQ:EYPT) Bolsa, Informe de interés en corto

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals Inc

Stephens &amp; Co. analyst Terry McEvoy downgrades Stock Yards Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) from Overweight to Equal-Weight and raises the price target from $70 to $76.

News

Downgrades

Price Target

Analyst Ratings

SYBT

Stephens & Co. Downgrades Stock Yards Bancorp to Equal-Weight, Raises Price Target to $76

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight rating and announces Price Target of $39.

Initiation

Stephens & Co. Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $39

Polymarket bettors appear skeptical about Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) reaching significant price milestones by December, with only a 6% chance assigned to Dogecoin hitting $1 and a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945659/dogecoin-to-69-cents-or-1-benzinga-readers-predict-how-high-it-could-fly-by-end-of-2024#:~:text=Only%2018%25%20of%20readers%20think,one%2Dyear%20high%20of%20%240.4359.">10% chance for $0.90.</a>
What Happened: These odds reflect the market&#8217;s doubts, despite the recent surge in Dogecoin's value following Donald Trump's election and Elon Musk's involvement with the newly established Department of Government Efficiency, dubbed &#8220;DOGE.&#8221;
Currently, the highest <a href="https://polymarket.com/event/what-price-will-dogecoin-hit-before-december?tid=1731690152725">chance </a>Polymarket assigns is a 59% probability for Dogecoin hitting $0.45 by the end of November, indicating tempered enthusiasm among investors.
The class-action lawsuit filed by a group of Dogecoin investors against Musk, accusing him of manipulating Dogecoin&#8217;s price in 2021, was <a href="https://www.reuters.com/legal/lawsuit-claiming-elon-musk-rigged-dogecoin-ends-2024-11-15/">dismissed</a> Friday, removing a legal overhang for the meme coin.
The investors argued Musk&#8217;s tweets and appearances, including on Saturday Night Live, artificially boosted Dogecoin's price, but a judge ultimately dismissed the claim as <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951069/dogecoins-flat-inflation-is-a-feature-not-a-bug-says-elon-musk">"aspirational and puffery."</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011875/solana-ripple-litecoin-etfs-may-be-on-the-table-under-trump-administration-industry-experts-think">Solana, Ripple, Litecoin ETFs May Be On The Table Under Trump Administration, Industry Experts Say</a>
Meanwhile, Musk's public support of Dogecoin remains strong; he recently endorsed its fixed inflation model as "<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951069/dogecoins-flat-inflation-is-a-feature-not-a-bug-says-elon-musk">a feature, not a bug</a>," positioning Dogecoin as a potentially stable currency.
Musk's ongoing advocacy has already led to substantial gains for Dogecoin post-election, with major players like Spirit Blockchain Capital also stepping in to build a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41947920/a-dogecoin-strategic-reserve-one-company-is-working-on-it">significant reserve of the coin</a>.
What&#8217;s Next: With discussions on the future of digital assets set to continue at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, attention will be on how regulatory and institutional interest could further shape Dogecoin's trajectory.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin To $1 Until December? Probably Not Happening, Polymarket Traders Say

Ladenburg Thalmann analyst Jeff Cohen downgrades Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) from Buy to Neutral.

BNGO

Ladenburg Thalmann Downgrades Bionano Genomics to Neutral

Barclays analyst Christine Cho maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Underperform and lowers the price target from $17 to $7.

SEDG

Barclays Maintains Underperform on SolarEdge Technologies, Lowers Price Target to $7

TD Cowen analyst Krish Sankar maintains Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) with a Hold and raises the price target from $45 to $50.

KLIC

TD Cowen Maintains Hold on Kulicke & Soffa Indus, Raises Price Target to $50

WIIM

Cue Biopharma shares are trading lower. The company reported Q3 financial results.

Jefferies analyst Corey Tarlowe maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and lowers the price target from $110 to $90.

Jefferies Maintains Buy on Dollar Gen, Lowers Price Target to $90

On Thursday, Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) announced the termination of its merger agreement with Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), citing <a target="_blank" href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles" rel="noreferrer noopener">uncertainty in the legal process.</a>
Following the termination of the merger agreement, Tapestry said it will redeem $6.1 billion in senior notes tied to the acquisition, paying 101% of their principal amount plus accrued interest, as per the Special Mandatory Redemption clause. Tapestry will also reimburse Capri $45 million for transaction-related expenses.
Here are the analysts&#8217; takes <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41550527/why-capri-holdings-stock-is-falling-today" rel="noreferrer noopener">on the&nbsp;termination news</a>:
Telsey Advisory Group: Analyst Dana Telsey maintained the Market Perform rating on Capri Holdings, lowering <a target="_blank" href="https://www.benzinga.com/quote/CPRI/analyst-ratings" rel="noreferrer noopener">the price forecast to $23 from $26</a>. Considering the string of disappointing results over the past several quarters, the analyst trimmed the price forecast.
Per the analyst, the company saw some initial successes, but the campaigns didn&#8217;t connect well with its core customers. It raised price points too quickly. Additionally, the brand reduced its signature products and introduced too much fashion, leading to deeper promotions to drive sales.
However, for Tapestry, the analyst raised the price forecast to $67 from $58, <a target="_blank" href="https://www.benzinga.com/quote/TPR/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>. Telsey is optimistic about earnings growth from the new buyback authorization and the company&#8217;s strong balance sheet.
The analyst sees no near-term acquisitions while focusing on improving Kate&#8217;s performance.
Meanwhile, the Coach brand remains resilient, with a 2% increase in constant currency last quarter, the analyst writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say" rel="noreferrer noopener">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders Say</a>
Guggenheim: Analyst Robert Drbul maintained a Neutral rating on Capri Holdings, citing the company&#8217;s deteriorating results over the past few years. The analyst pointed out &#8220;multiple missteps&#8221; by the company, including focus on younger consumers, rapid price increases, and reduced promotions.
Drbul also criticized the reduction of signature styles and overemphasis on &#8220;fashion&#8221; at Michael Kors. At Versace, the shift toward luxury/quality alienated the aspirational consumer by removing statement items. The analyst lowered FY25/FY26 EPS estimates to $1.50/$2.00, down from $1.85/$2.10. Per Drbul, Capri&#8217;s current low valuation could attract offers.
Drbul reiterated the Buy rating on Tapestry, raising the price forecast to $70 from $60. The analyst notes Tapestry will focus on strengthening Coach and Kate Spade, not pursuing acquisitions for now. With the Capri merger behind, Drbul sees value in Tapestry&#8217;s current portfolio.
The company is expected to benefit from pricing power in FY25 and may reach a 19% operating margin, with long-term potential to return to pre-COVID margins, driven by DTC growth and expansion in Asia, Drbul writes.
JP Morgan: Analyst Matthew R. Boss reiterated the Neutral rating on Capri Holdings, with a price forecast of $15. The analyst projects FY25 EPS of $1.44, 17% below consensus, with a 14% year over year revenue decline and a 45bps gross margin contraction.&nbsp;
For the second half of 2025, the analyst projects revenues to be down 13% (an improvement from the first half&#8217;s -15%), gross margins to decrease by 10bps year over year (compared to the first half&#8217;s -80bps).
Capri Holdings&#8217; shift to a higher direct-to-consumer sales mix has boosted full-price selling, but also increased operating expenses, Boss writes. The analyst warns that with limited opportunities to cut SG&amp;A costs, this could be challenging amid a slowing top-line growth.
Price Action: CPRI shares are trading higher by 1.80% to $20.89 at last check Friday, while TPR shares are trading lower by 0.98% to $57.26.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft" target="_blank" rel="noreferrer noopener">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></li>
</ul>

Analyst Color

Equities

Reiteration

Markets

Trading Ideas

General

CPRI

Tapestry Poised For Solid Growth After Capri Merger Termination, Analysts Cite Struggles And Missteps At Capri

TD Cowen analyst Krish Sankar maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $250 to $230.

AMAT

TD Cowen Maintains Buy on Applied Mat, Lowers Price Target to $230

Whales with a lot of money to spend have taken a noticeably bullish stance on Morgan Stanley.
Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 23 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $332,437 and 16, calls, for a total amount of $1,219,604.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $185.0 for Morgan Stanley during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Morgan Stanley's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Morgan Stanley's significant trades, within a strike price range of $95.0 to $185.0, over the past month.
<h3>Morgan Stanley Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696369_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$140.00</td>
<td>$340.0K</td>
<td>3.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.85</td>
<td>$5.15</td>
<td>$6.85</td>
<td>$185.00</td>
<td>$136.8K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$125.2K</td>
<td>6.4K</td>
<td>293</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.75</td>
<td>$140.00</td>
<td>$103.2K</td>
<td>224</td>
<td>75</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$115.00</td>
<td>$85.0K</td>
<td>7.3K</td>
<td>47</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
In light of the recent options history for Morgan Stanley, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Morgan Stanley Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,092,834, with MS's price up by 0.76%, positioned at $133.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Morgan Stanley</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $128.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Morgan Stanley, which currently sits at a price target of $121. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Underweight rating for Morgan Stanley, targeting a price of $107. 
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $142. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Morgan Stanley, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Morgan Stanley: Analyzing the Surge in Options Activity

Investors with significant funds have taken a bullish position in Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in LDOS usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Leidos Holdings. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 50% bearish. Of all the options we discovered, 7 are puts, valued at $974,530, and there was a single call, worth $29,500.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $170.0 for Leidos Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Leidos Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Leidos Holdings's significant trades, within a strike price range of $130.0 to $170.0, over the past month.
<h3>Leidos Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696364_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$4.8</td>
<td>$5.4</td>
<td>$155.00</td>
<td>$346.1K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$8.4</td>
<td>$7.0</td>
<td>$8.4</td>
<td>$130.00</td>
<td>$168.0K</td>
<td>1.5K</td>
<td>77</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.7</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$165.00</td>
<td>$148.7K</td>
<td>127</td>
<td>133</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$155.00</td>
<td>$111.9K</td>
<td>0</td>
<td>232</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$5.8</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$96.5K</td>
<td>202</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Leidos Holdings</h3>
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in three reportable segments; Defense Solutions, Civil, and Health. Defense Solutions provides technologically latest services, solutions, and products to a broad customer base. It generates key revenue from Defense Solutions.
After a thorough review of the options trading surrounding Leidos Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Leidos Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,765,461, the LDOS's price is down by -5.9%, now at $158.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Leidos Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $212.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Leidos Holdings, which currently sits at a price target of $200. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Leidos Holdings with a target price of $210. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Leidos Holdings, which currently sits at a price target of $230. 
&#x2A; An analyst from Baird persists with their Outperform rating on Leidos Holdings, maintaining a target price of $218. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Leidos Holdings, maintaining a target price of $205. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Leidos Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

LDOS

Unpacking the Latest Options Trading Trends in Leidos Holdings

High-rolling investors have positioned themselves bullish on NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for NextNav. This is not a typical pattern.
The sentiment among these major traders is split, with 69% bullish and 23% bearish. Among all the options we identified, there was one put, amounting to $105,000, and 12 calls, totaling $504,800.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $17.0 for NextNav over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NextNav's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextNav's whale activity within a strike price range from $3.0 to $17.0 in the last 30 days. 
<h3>NextNav Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696359_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.4</td>
<td>$3.00</td>
<td>$125.4K</td>
<td>2.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>NN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.75</td>
<td>$15.00</td>
<td>$105.0K</td>
<td>26</td>
<td align="right">600</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$17.00</td>
<td>$46.9K</td>
<td>566</td>
<td align="right">70</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.9</td>
<td>$6.7</td>
<td>$7.84</td>
<td>$15.00</td>
<td>$39.4K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$12.00</td>
<td>$39.3K</td>
<td>693</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About NextNav</h3>
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation and Timing services in the absence of GPS.
In light of the recent options history for NextNav, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of NextNav</h3>
<ul>
<li>Trading volume stands at 568,994, with NN's price up by 0.85%, positioned at $14.27.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 117 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NextNav options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in NextNav

TD Cowen analyst Lance Vitanza maintains Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) with a Hold and lowers the price target from $20 to $16.

INSG

TD Cowen Maintains Hold on Inseego, Lowers Price Target to $16

Jefferies analyst Corey Tarlowe maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $95 to $105.

Jefferies Maintains Buy on BJ's Wholesale Club, Raises Price Target to $105

TD Cowen analyst Bryan Bergin maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $230 to $240.

GLOB

TD Cowen Maintains Buy on Globant, Raises Price Target to $240

Jefferies analyst Corey Tarlowe maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

Jefferies Maintains Buy on Walmart, Raises Price Target to $100

ABAT

American Battery Technology shares are trading lower. The company reported Q1 financial results.

TD Cowen analyst Doug Creutz maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Hold and raises the price target from $108 to $123.

TD Cowen Maintains Hold on Walt Disney, Raises Price Target to $123

Jefferies analyst Samad Samana maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $230 to $215.

NICE

Jefferies Maintains Buy on NICE, Lowers Price Target to $215

EyePoint Pharmaceuticals prices $140M share offering

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Reports Q3 revenue $10.524M, consensus $10.42M. "We made tremendous progress across our pipeline in recent months, including dosing the first patie...

EyePoint reports Q3 EPS (54c), consensus (55c)

The company said, "We expect the cash, cash equivalents and investments on September 30, 2024, along with the net proceeds from the October $161.0 ...

EyePoint expect cash to fund operations into 2027

EyePoint Pharmaceuticals GAAP EPS of -$0.54, revenue of $10.5M

TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report) today and set a price target of $20.0...

EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating

Eyepoint Pharma ( ($EYPT) ) has released its Q3 earnings. Here is a breakdown of the information Eyepoint Pharma presented to its investors. EyePoi...

EyePoint Pharmaceuticals Advances in Retinal Therapeutics

EyePoint Pharmaceuticals (EYPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana C...

EyePoint Pharmaceuticals: Buy Rating Backed by Promising Clinical Developments and Strong Financial Position

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

AMRN

BMRN

EYPT

GLYC

HOTH

INCY

MEIP

MNKD

RVNC

Management

Press Releases

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Financing

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Health Care

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Comments

EyePoint Pharmaceuticals

Interés en corto

EyePoint Pharmaceuticals (NASDAQ:EYPT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL